A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα [tumour necrosis factor alpha] Inhibitor Therapy.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2013
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 28 May 2011 Primary endpoint 'American-College-of-Rheumatology-50%-response-criteria' has not been met, according to results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History